The Hemorrhagic Shock drugs in development market research report provides comprehensive information on the therapeutics under development for Hemorrhagic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemorrhagic Shock. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemorrhagic Shock and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Hemorrhagic Shock by 16 companies/universities/institutes. The top development phase for Hemorrhagic Shock is preclinical with 11 drugs in that stage. The Hemorrhagic Shock pipeline has 16 drugs in development by companies and two by universities/ institutes. Some of the companies in the Hemorrhagic Shock pipeline products market are: NuvOx Pharma, TheraSource and New Beta Innovation.
The key targets in the Hemorrhagic Shock pipeline products market include Protein Arginine Deiminase Type 4 (HL 60 PAD or PADI H Protein or Peptidylarginine Deiminase IV or PADI4 or EC 3.5.3.15), Leukotriene B4 (LTB4), and Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF).
The key mechanisms of action in the Hemorrhagic Shock pipeline product include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor with one drug in Phase I. The Hemorrhagic Shock pipeline products include 11 routes of administration with the top ROA being Intravenous and seven key molecule types in the Hemorrhagic Shock pipeline products market including Small Molecule, and Recombinant Protein.
Hemorrhagic Shock overview
Hemorrhagic shock is hypovolemic shock from blood loss. Traumatic injury is by far the most common cause of hemorrhagic shock. Hypovolemic shock is a form of shock caused by severe hypovolemia (insufficient blood volume or extracellular fluid in the body). It could be the result of severe dehydration through a variety of mechanisms or blood loss. Hypovolemic shock is a medical emergency; if left untreated, the insufficient blood flow can cause damage to organs, leading to multiple organ failure.
For a complete picture of Hemorrhagic Shock’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
